JP2022512642A5 - - Google Patents

Info

Publication number
JP2022512642A5
JP2022512642A5 JP2021519595A JP2021519595A JP2022512642A5 JP 2022512642 A5 JP2022512642 A5 JP 2022512642A5 JP 2021519595 A JP2021519595 A JP 2021519595A JP 2021519595 A JP2021519595 A JP 2021519595A JP 2022512642 A5 JP2022512642 A5 JP 2022512642A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
sequence shown
linked amino
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512642A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055155 external-priority patent/WO2020076799A1/en
Publication of JP2022512642A publication Critical patent/JP2022512642A/ja
Publication of JP2022512642A5 publication Critical patent/JP2022512642A5/ja
Pending legal-status Critical Current

Links

JP2021519595A 2018-10-09 2019-10-08 がんを治療するための抗MerTK抗体 Pending JP2022512642A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743507P 2018-10-09 2018-10-09
US62/743,507 2018-10-09
PCT/US2019/055155 WO2020076799A1 (en) 2018-10-09 2019-10-08 Anti-mertk antibodies for treating cancer

Publications (2)

Publication Number Publication Date
JP2022512642A JP2022512642A (ja) 2022-02-07
JP2022512642A5 true JP2022512642A5 (cg-RX-API-DMAC7.html) 2022-10-18

Family

ID=68345048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519595A Pending JP2022512642A (ja) 2018-10-09 2019-10-08 がんを治療するための抗MerTK抗体

Country Status (6)

Country Link
US (1) US20210395392A1 (cg-RX-API-DMAC7.html)
EP (1) EP3864046A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022512642A (cg-RX-API-DMAC7.html)
KR (1) KR20210072059A (cg-RX-API-DMAC7.html)
CN (1) CN112839962A (cg-RX-API-DMAC7.html)
WO (1) WO2020076799A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002967A (ko) * 2019-04-19 2022-01-07 제넨테크, 인크. 항 mertk 항체 및 이의 사용 방법
PE20221326A1 (es) 2019-12-13 2022-09-09 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos
WO2021202590A1 (en) * 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
WO2022164288A1 (ko) 2021-01-29 2022-08-04 한국과학기술원 비염증성 식세포작용 유도 활성을 갖는 융합분자
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh) * 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
KR20240082341A (ko) 2021-10-15 2024-06-10 치오메 바이오사이언스 가부시키가이샤 MerTK에 특이적으로 결합하는 항체 또는 이의 단편, 및 항종양제
CN114591431B (zh) * 2022-05-11 2022-08-12 迈威(上海)生物科技股份有限公司 抗人gas6抗体或其抗原结合片段及其应用
CN120484126B (zh) * 2022-07-28 2025-11-18 乐普创一生物科技(上海)有限公司 抗MerTK抗体及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
EP3789039A1 (en) * 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE

Similar Documents

Publication Publication Date Title
JP2023519254A5 (cg-RX-API-DMAC7.html)
JP7171617B2 (ja) 抗SIRPα抗体
US12384853B2 (en) Anti-HER2/PD1 bispecific antibody
JP5723279B2 (ja) 抗cxcr4抗体および癌治療のためのそれらの使用
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2021520201A5 (cg-RX-API-DMAC7.html)
JP2021531764A5 (cg-RX-API-DMAC7.html)
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2022525071A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2024534265A5 (cg-RX-API-DMAC7.html)
JP2024514530A5 (cg-RX-API-DMAC7.html)
JP2024532886A5 (cg-RX-API-DMAC7.html)
JP2024535930A5 (cg-RX-API-DMAC7.html)
JP2022526841A5 (cg-RX-API-DMAC7.html)
JP2023037000A5 (cg-RX-API-DMAC7.html)
JP2022513729A5 (cg-RX-API-DMAC7.html)
JP2025503229A5 (cg-RX-API-DMAC7.html)
JP2024525916A5 (cg-RX-API-DMAC7.html)
JP2024533457A5 (cg-RX-API-DMAC7.html)
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses